Oric Pharmaceuticals (NASDAQ:ORIC) Now Covered by Analysts at BTIG Research

Posted by Geri Gentry on Sep 23rd, 2026

Analysts at BTIG Research started coverage on shares of Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) in a research report issued on Wednesday, MarketBeat reports. The brokerage set a “buy” rating and a $26.00 price target on the stock. BTIG Research’s target price suggests a potential upside of 92.59% from the company’s previous close.

ORIC has been the subject of several other research reports. Stifel Nicolaus assumed coverage on shares of Oric Pharmaceuticals in a research note on Friday, June 12th. They set a “buy” rating and a $14.00 price objective for the company. Benchmark reiterated a “buy” rating on shares of Oric Pharmaceuticals in a research note on Monday, June 8th. Wall Street Zen raised shares of Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, July 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Friday, July 17th. Finally, HC Wainwright upped their price target on shares of Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Oric Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $20.18.

Get Our Latest Stock Report on ORIC

Oric Pharmaceuticals Stock Up 6.6%

Shares of NASDAQ ORIC opened at $13.50 on Wednesday. The company has a market cap of $1.40 billion, a P/E ratio of -10.00 and a beta of 1.00. Oric Pharmaceuticals has a 52 week low of $7.23 and a 52 week high of $14.93. The business has a 50-day simple moving average of $12.64 and a two-hundred day simple moving average of $10.84.

Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.02). Equities research analysts anticipate that Oric Pharmaceuticals will post -1.53 EPS for the current year.

Insider Transactions at Oric Pharmaceuticals

In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 77,000 shares of Oric Pharmaceuticals stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $13.69, for a total transaction of $1,054,130.00. Following the completion of the sale, the chief financial officer directly owned 69,828 shares in the company, valued at $955,945.32. The trade was a 52.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.70% of the stock is currently owned by insiders.

Institutional Trading of Oric Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in Oric Pharmaceuticals in the second quarter worth $73,904,000. Siren L.L.C. raised its position in Oric Pharmaceuticals by 197.6% during the first quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock valued at $37,987,000 after purchasing an additional 1,990,617 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Oric Pharmaceuticals by 19.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company’s stock worth $18,637,000 after purchasing an additional 244,060 shares during the last quarter. Bank of America Corp DE lifted its stake in Oric Pharmaceuticals by 105.5% during the first quarter. Bank of America Corp DE now owns 1,043,159 shares of the company’s stock worth $13,217,000 after purchasing an additional 535,649 shares during the last quarter. Finally, Algert Global LLC boosted its holdings in shares of Oric Pharmaceuticals by 791.3% in the 2nd quarter. Algert Global LLC now owns 1,215,293 shares of the company’s stock worth $13,162,000 after purchasing an additional 1,078,943 shares in the last quarter. Hedge funds and other institutional investors own 95.05% of the company’s stock.

About Oric Pharmaceuticals

(Get Free Report)

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. The company seeks to address treatment resistance by targeting biological mechanisms that allow tumors to survive or evade existing therapies, with an emphasis on restoring or enhancing the effectiveness of anti-cancer treatment.

Oric’s research and development portfolio has included small-molecule drug candidates aimed at targets such as CD73 and the polycomb repressive complex 2 (PRC2).